Zydus Wellness reported a 7% year-on-year decline in net profit for the first quarter of fiscal 2027, posting ₹119 crore despite a robust 66.7% surge in net sales to ₹1,430 crore.
The divergence between top-line momentum and bottom-line contraction highlights intensifying margin pressure within India’s consumer health and wellness segment.
Reddy’s Laboratories, which reported a sharp 69% profit decline in the same period due to different headwinds, including generic drug pricing pressures in key export markets.
The Ahmedabad-based company, part of the Zydus Group, saw its revenue more than double compared to the prior-year period, driven by strong volume growth and market share gains.
However, profitability was eroded by rising input costs and aggressive promotional spending aimed at defending market position against competitors.
This pattern mirrors broader trends in the Indian pharmaceutical and wellness industry, where companies are prioritizing volume expansion over immediate margin optimization.
The results stand in contrast to peers such as Dr. Reddy’s Laboratories, which reported a sharp 69% profit decline in the same period due to different headwinds, including generic drug pricing pressures in key export markets.